One of the world’s leading events in life sciences is held in Israel and is called the IATI BioMed. As a new initiative this year, MEDinIsrael – a conference hosted by the Ministry of Foreign Affairs, Ministry of Industry, Trade & Labor, Ministry of Health and Israel Export Institute – has planned to place their event simultaneously with IATI BioMed 2013. The joint initiatives combined could very well be one of the best opportunities to the life science sector this year. Israel is known of being a direct life science path into the US.
According to the United States Patent and Trademark Office, Israel has more Medical Device patents per capita than any other country in the world, and ranks 4 in Bio-Pharma Patents per capita. In Europe they rank the second per capita of private biotech companies’ products in pipeline. The life science industry in Israel can be divided in the following sectors: 1) Medical devices, 2) HealthCare IT, 3) Biotechnology, 4) Pharmaceuticals and 5) Life science services.
Lasse Holm Grønning from the Danish Embassy in Tel Aviv (Commercial and Innovation Advisor) explains which market opportunities there are to be found in Israel for companies within the sector.
The Ministry of Science, Innovation and Higher Education and the Embassy has for several years organized a booth at the conference, in which Danish scientists and companies have been represented and received the Embassy’s matchmaking service. This has proven to be very fruitful for enterprises and researchers looking to find collaborators, and for entering the Israeli – and the global – market.
Lasse Holm Grønning, Head of Team Trade and Innovation, Royal Danish Embassy, Tel Aviv, firstname.lastname@example.org & Niclas Maabari Skovbjerg, intern, Team Trade and Innovation
Mere fra MedWatch
Biotekselskabet Evaxion Biotech, der arbejder med udviklingen af vacciner og immunterapi baseret på kunstig intelligens, har sikret sig muligheden for at rejse 100 mio. dollar til finansieringen af selskabets drift i tider med uro på de finansielle markeder. Rettidig omhu, lyder det fra den adm. direktør.